Biogen Inc (BIIB)
Total asset turnover
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Revenue | US$ in thousands | 9,835,600 | 10,173,400 | 10,981,700 | 13,444,600 | 14,377,900 |
Total assets | US$ in thousands | 26,844,800 | 24,554,100 | 23,877,300 | 24,618,900 | 27,234,300 |
Total asset turnover | 0.37 | 0.41 | 0.46 | 0.55 | 0.53 |
December 31, 2023 calculation
Total asset turnover = Revenue ÷ Total assets
= $9,835,600K ÷ $26,844,800K
= 0.37
The total asset turnover ratio for Biogen Inc has been declining over the past five years, decreasing from 0.53 in 2019 to 0.37 in 2023. This indicates that the company generated less revenue for each dollar of assets it held in 2023 compared to previous years. A lower total asset turnover ratio can signify inefficiency in asset utilization or potential challenges in generating sales from its asset base. Further analysis and comparison with industry peers may provide insights into the underlying causes of this trend and potential areas for improvement in operational performance.
Peer comparison
Dec 31, 2023
Company name
Symbol
Total asset turnover
Biogen Inc
BIIB
0.37
Amgen Inc
AMGN
0.26
Bio-Techne Corp
TECH
0.43
Gilead Sciences Inc
GILD
0.42
Halozyme Therapeutics Inc
HALO
0.47
Krystal Biotech Inc
KRYS
0.07
Moderna Inc
MRNA
0.37
Neurocrine Biosciences Inc
NBIX
0.58
Regenxbio Inc
RGNX
0.15
Repligen Corporation
RGEN
0.22
Vericel Corp Ord
VCEL
0.56